ICYMI, REGENXBIO’s VP of Regulatory and Corporate Strategy, Nina Hunter, recently joined Cell & Gene Live to discuss the regulatory challenges and strategies involved in bringing innovative AAV therapies to patients. Listen to the recording here: https://lnkd.in/e5WKrNWd
